Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Current Leases (2019 - 2023)

Alaunos Therapeutics (TCRT) has disclosed Current Leases for 5 consecutive years, with $307000.0 as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Current Leases fell 43.36% year-over-year to $307000.0, compared with a TTM value of $307000.0 through Sep 2023, down 43.36%, and an annual FY2022 reading of $558000.0, down 23.46% over the prior year.
  • Current Leases was $307000.0 for Q3 2023 at Alaunos Therapeutics, down from $339000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $866000.0 in Q3 2020 and bottomed at $307000.0 in Q3 2023.
  • Average Current Leases over 5 years is $660333.3, with a median of $693500.0 recorded in 2019.
  • The sharpest move saw Current Leases increased 28.57% in 2020, then tumbled 43.36% in 2023.
  • Year by year, Current Leases stood at $677000.0 in 2019, then grew by 20.97% to $819000.0 in 2020, then fell by 10.99% to $729000.0 in 2021, then decreased by 23.46% to $558000.0 in 2022, then plummeted by 44.98% to $307000.0 in 2023.
  • Business Quant data shows Current Leases for TCRT at $307000.0 in Q3 2023, $339000.0 in Q2 2023, and $575000.0 in Q1 2023.